Access eDOT Toolkit
The Centers for Disease Control and Prevention (CDC), Division of Tuberculosis Elimination (DTBE) is pleased to announce the release of "Implementing an Electronic Directly Observed Therapy (eDOT) Program: A Toolkit for Tuberculosis (TB) Programs".The purpose of the toolkit is to assist TB programs in developing and implementing an eDOT program. The toolkit provides a general overview of eDOT, steps for implementing a TB eDOT program, and sample forms that can be tailored to fit individual TB program needs.
Access eDOT Toolkit
A new education module entitled "Landscape and Language of Molecular Diagnostics for TB Drug Resistance" was developed by and is now available from the Association of Public Health Laboratories and the CDC. This module provides a brief overview of basic principles of molecular biology and test platforms used for molecular testing of Mycobacterium tuberculosis as a basis for understanding how mutations are associated with drug resistance in TB and what reporting language might be used to describe resistance results.
Link to full list of training modules:
Questions about the module can be sent to Stephanie Johnston, MS at email@example.com.
The CDC has recently published Modules 6 and 8 of the Self-Study Modules in Spanish. These Self-Study Modules on Tuberculosis are a series of educational modules designed to provide information about TB in a self-study format. The series consists of a total of nine modules that are separated into two courses. The first course, Modules 1-5, provides basic information on TB. The second course, Modules 6-9, provides more specific TB programmatic information.
Newly Published: 2016 Clinical Practice Guidelines for Diagnosis of Tuberculosis in Adults and Children
Just released by the CDC, the American Thoracic Society, and the Infectious Diseases Society of America, these guidelines provide recommendations on the diagnosis of latent TB infection, pulmonary TB, and extrapulmonary TB in adults and children, updating guidelines that were published in 2000.
The guidelines provide evidence-based recommendations that were developed with the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology. GRADE involves structured literature review, systematic reviews and meta-analyses of combined data, and expert discussion to assess the certainty in the evidence and determine the strength of each recommendation.
The twenty-three evidence-based recommendations include guidance for clinicians on how to employ newer tests to diagnose TB disease and latent TB infection, including interferon-gamma release assays (IGRAs) and molecular diagnostics. Although TB is less common in the United States than in other parts of the world, clinicians should consider testing patients who have a higher-risk for TB infection, including patients who were born in or who frequently travel to countries where TB disease is common; patients who live or have lived in large group settings, such as homeless shelters or prisons and jails; or those with other risk factors, as described in the guidelines.
Earlier this year, the Centers for Disease Control and Prevention (CDC) released provisional 2015 surveillance data on reported tuberculosis (TB) cases in the United States. The full report, entitled Reported Tuberculosis in the United States, 2015, is now available online.
The first increase in TB cases in the United States in 23 years underscores the need for more comprehensive public health approaches in TB prevention and control. Eliminating TB in the United States requires an expanded approach to test and treat latent TB infection, and strengthen existing systems to stop TB transmission.
CDC has developed a slide set, fact sheet, infographic, and web graphics with highlights from the surveillance report to support TB education and outreach to clinicians, health care agencies, and community organizations.
The 2017 National TB Conference is being held on April 18-21, 2017, at the Atlanta Marriott Marquis in Atlanta, GA, USA.
The National TB Conference welcomes the submission of abstracts for poster presentation on all aspects of tuberculosis control, including epidemiologic, clinical, basic science, nursing, social, behavioral, psychosocial, and educational as well as outcomes of program initiatives. Abstracts are due Tuesday, January 3, 2017 at 11:59 p.m.
The 2017 National TB Conference will kick off with an evening reception and poster discussion session on Tuesday, April 18 from 5:00-6:30 p.m. This session will be held in conjunction with our APHL colleagues.
More Information and Online Abstract Submission Form
Tuberculosis (TB) cannot be eliminated in the United States without increased efforts to test and treat latent TB infection. Today, the U.S. Preventive Services Task Force (USPSTF) issued a recommendation that supports CDC guidance to test for latent tuberculosis infection in populations that are at increased risk. These groups include:
This recommendation provides a new opportunity for the TB community to draw attention to latent TB infection and educate the public, health care providers, at-risk populations, and policy makers on the importance of targeted testing and treatment for latent TB infection. CDC has latent TB infection resources that partners can use as part of outreach and education with affected communities and the health care providers serving these communities. A PDF document with CDC key messages and a list of helpful resources is attached.
Thank you for your work and commitment to eliminate TB.
Philip LoBue, MD, FACP, FCCP
Director, Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
The Centers for Disease Control and Prevention (CDC), Division of Tuberculosis Elimination (DTBE), is pleased to announce the release of the online course, Interactive Core Curriculum on Tuberculosis: What the Clinician Should Know. This is a web-based course that provides clinicians with the basic concepts of diagnosing and treating latent TB infection and TB disease. Continuing education is available free of charge.Please share this course with clinicians and staff who are involved in providing TB diagnosis and treatment services. Additionally, please add the Interactive Core Curriculum to your TB trainings and resource list.
If you have any questions about this course, please contact Molly Dowling at firstname.lastname@example.org.
The CDC's Division of Tuberculosis Elimination (DTBE) Releases its 2014 Surveillance Data on Reported TB Cases in the U.S
The full report, entitled Reported Tuberculosis In the United States
is now accessible online. The DTBE reviews data from 60 reporting areas to compile the annual report. Among many key findings, the surveillance report confirmed that last year's decline in the rate of TB was the smallest decrease in more than a decade. This minor decrease underscores the importance of strengthening the strategies in surveillance, contact investigations, and testing and treating contacts with latent TB infection (LTBI). Populations at highest risk for TB (such as persons born in high-burden countries) must also be a focus.
The CDC Division of Tuberculosis Elimination (DTBE) is pleased to announce the implementation of phenotypic drug susceptibility testing of SIRTURO (Bedaquiline) as part of CDC’s Reference Laboratory services in the DTBE Laboratory Branch. Instructions regarding submission of isolates and additional contact information are provided here.
If you have questions regarding this expanded service, please contact Dr. Beverly Metchock, Reference Laboratory Team Lead (email@example.com, 404-639-1285). If your laboratory has archived isolates for BDQ Testing, please contact Dr. Metchock prior to shipping.
If you have questions regarding the BDQ Patient-Exposure Registry, please contact Dr. Sundari Mase, Medical Team Lead for the DTBE Field Services and Evaluation Branch (FSEB) at firstname.lastname@example.org or 404-639-5336